MTX Discontinuation and Vaccine Response

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

277 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate whether a short term discontinuation of methotrexate (MTX) will improve the vaccination efficacy to seasonal influenza vaccination without deteriorating RA disease activity in a randomized clinical trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

2-week dc of MTX and Influenza Vaccination in RA

NCT02897011

Rheumatoid Arthritis Influenza Methotrexate

UNKNOWN NA

One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.

NCT05069714

Rheumatoid Arthritis Autoimmune Diseases Influenza +1 more

COMPLETED PHASE3

Effect of MTX Discontinuation on Shingrix Response in RA

NCT06574594

Rheumatoid Arthritis

RECRUITING NA

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

NCT00928512

Rheumatoid Arthritis

COMPLETED PHASE2

MTX Hold During Covid-19 Booster

NCT05313061

Rheumatoid Arthritis

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects the joints as the main target of the inflammation. Patients with RA require chronic treatment with disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX), which constitutes the mainstay of treatment.

Underlying immune dysfunction and the additional immune suppression associated with treatment render patients with RA more susceptible to infection. Thus, vaccination against preventable diseases including influenza, pneumococcal pneumonia and hepatitis B is recommended for all RA patients who are subject to treatment with immunesupprssive drugs, unless there is a contraindication to the use of vaccination. However, low dose of glucocorticoids, conventional DMARDs and biological DMARDs including tumor necrosis factor inhibitors have been reported to substantially decrease vaccine response (4); MTX has been reported to be associated with a decreased response to seasonal influenza vaccination by up to 15%.

To optimize a vaccine response, vaccination should be administrated before the treatment with immunesuppressive medications is initiated. However, most patients with RA are already on stable dose of DMARDs at the time of when vaccinations, especially vaccine against seasonal influenza that needs annual administration, are considered. Alternatively, temporarily discontinuation of DMARDs might restore normal immune response to and so improve the efficacy of vaccination.

Although a short term discontinuation of DMARDs during perioperative period has not been associated with increased disease activity the longer discontinuation of DMARDs might lead to a significant aggravation of RA disease activity. To optimize the vaccine response, a short term discontinuation of DMARDs could be considered if this approach proves to be safe and effective.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (No MTX Hold before Vaccination)

Group 1 will continue MTX

Group Type EXPERIMENTAL

Methotrexate

Intervention Type DRUG

Methotrexate will be continued

Seasonal Influenza vaccine

Intervention Type BIOLOGICAL

all subjects will be vaccinated with a seasonal influenza vaccine

Group 2 (MTX hold 4 Weeks before vaccination)

Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination

Group Type EXPERIMENTAL

Methotrexate

Intervention Type DRUG

Methotrexate will be continued

Seasonal Influenza vaccine

Intervention Type BIOLOGICAL

all subjects will be vaccinated with a seasonal influenza vaccine

Group 3 (MTX hold 2 Weeks before Vaccination)

Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination

Group Type EXPERIMENTAL

Methotrexate

Intervention Type DRUG

Methotrexate will be continued

Seasonal Influenza vaccine

Intervention Type BIOLOGICAL

all subjects will be vaccinated with a seasonal influenza vaccine

Group 4 (MTX hold on Day of Vaccination)

Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.

Group Type EXPERIMENTAL

Methotrexate

Intervention Type DRUG

Methotrexate will be continued

Seasonal Influenza vaccine

Intervention Type BIOLOGICAL

all subjects will be vaccinated with a seasonal influenza vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methotrexate

Methotrexate will be continued

Intervention Type DRUG

Seasonal Influenza vaccine

all subjects will be vaccinated with a seasonal influenza vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females \> 18 years at time of consent
* Have a diagnosis of RA per ACR criteria
* Must understand and voluntarily sign an informed consent form including writing consent for data protection
* Stable doses of methotrexate over the preceding 6 weeks

Exclusion Criteria

* Pregnant or lactating females
* Previous anaphylactic response to vaccine components or to egg.
* Acute infection with T \>38°C at the time of vaccination
* History of Guillain-Barre syndrome or demyelinating syndromes
* Previous vaccination with any live vaccine 4 weeks before or any inactivated vaccine 2 weeks before the study
* Blood transfusion within 6 months
* Active rheumatoid arthritis necessitating a recent change in the drug regimen
* Any other rheumatic disease such as systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary Sjogren's disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No